NEPWA
SRPT icon

New England Private Wealth Advisors’s Sarepta Therapeutics SRPT Stock Holding History

New England Private Wealth Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-2,494
Closed -$379K – 176
2019
Q2 		$379K Buy
2,494
+506
+25% +$61.5K 0.09% 107
2019
Q1 		$237K Buy
+1,988
New +$256K 0.06% 133
2018
Q4 		– Sell
-1,416
Closed -$229K – 160
2018
Q3 		$229K Buy
+1,416
New +$194K 0.06% 132

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

New England Private Wealth Advisors's SRPT Position: Q3 2019 in Review

New England Private Wealth Advisors sold out of Sarepta Therapeutics (SRPT) in Q3 2019, closing a stake of 2,494 shares — an estimated $379K sold.

New England Private Wealth Advisors first reported a position in SRPT in Q3 2018 and held it in 3 quarters. The position peaked at $379K in Q2 2019. 341 funds tracked by Wall St. Rank hold SRPT as of Q3 2019.

  • New England Private Wealth Advisors reported no remaining Sarepta Therapeutics position as of Q3 2019 after selling out during the quarter.
  • New England Private Wealth Advisors sold 2,494 Sarepta Therapeutics shares in Q3 2019, an estimated $379K.
  • New England Private Wealth Advisors first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 3 quarters.
  • New England Private Wealth Advisors's Sarepta Therapeutics position peaked at $379K in Q2 2019.
  • 341 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2019.

Based on New England Private Wealth Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.